Navigation Links
Potentia Pharmaceuticals' POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II
Date:5/4/2009

POT-4 well tolerated by all subjects and sustained levels of drug reported after one treatment

LOUISVILLE, Ky., May 4 /PRNewswire/ -- Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that it successfully completed its Phase I ASaP (Assessment of Safety of Intravitreal POT-4 Therapy for Patients with Neovascular Age-Related Macular Degeneration) clinical trial for the company's leading drug candidate, POT-4.

The ASaP trial was an open label, first-in-man, multi-center, single escalating dose study. The primary safety endpoint of this trial was achieved and the drug was well tolerated by all subjects at all doses tested, based on clinical signs, ophthalmic examinations, and laboratory results. No drug-related serious adverse events and no identifiable intraocular inflammation were reported. Additionally, significant sustained levels of POT-4 were consistently measured via serum analysis in subjects receiving the highest dose studied. The current POT-4 formulation is expected to provide sustained therapeutic ocular levels of the drug for several months following a single injection.

The data accumulated so far support the implementation of a comprehensive Phase II clinical program to further define the safety, efficacy and pharmacokinetic profile of POT-4 as a treatment for both dry and wet AMD.

"The safety and pharmacokinetic data strongly support the further development of POT-4 as a first-in-class treatment for patients with AMD," said Cedric Francois, President and CEO of Potentia Pharmaceuticals. "We believe that POT-4 has significant promise based on these early-stage findings and look forward to further testing of POT-4 in this disease, which is so prevalent and devastating to those affected by it."

About POT-4

POT-4 is a complement factor C3
'/>"/>

SOURCE Potentia Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
2. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
3. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
4. Study Shows Leconotide, an Investigative Calcium Channel Blocker, Has Potential as a Selective, Efficacious, Non-Opioid Pain Treatment
5. ESBATechs Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
6. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
7. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
8. Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids
9. Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkins Lymphoma
10. Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease
11. NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  The orthopedic specialists at Midwest Orthopaedics ... orthopedic group by US News & World Report, are ... of free, public seminars to discuss partial and total ... come to see the knee physicians at Midwest Orthopaedics ... at Munster Specialty Surgery Center. The ...
(Date:9/30/2014)... PAUL, Minn. , Sept. 30, 2014 ... the United States abused prescription pain relievers ... include detoxification or maintenance treatment, which entails the use ... costs of these treatments are important when developing and ... by pharmacy benefit manager Prime Therapeutics LLC ...
(Date:9/30/2014)... 2014 Headquartered in Anaheim, California ... company comprised of several specialized partners focused on leveraging ... proven expertise of its team of professionals to improve ... line of more than 10 professional diagnostic tests for ... than 8 retail consumer tests is proud to announce ...
Breaking Medicine Technology:"Knee Pain Solutions for Active Adults" Complimentary Seminars Open to the Public 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 3WholeHealth Products Announces The Discovery Of The "Autism And Fragile X" Microwell And Rapid Diagnostic Test 2
... Regado Biosciences, Inc., a privately held company ... control agents, announces one poster presentation and two ... Scientific Sessions meeting on November 14, 2011 during ... All three presentations highlight results from Regado,s pipeline ...
... Md., Nov. 14, 2011 Science, public health, ... Administration. Information in this document is designed for credentialed ... as of November 14, 2011. ... not contain any regulatory or enforcement actions due to ...
Cached Medicine Technology:Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH 2Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH 3Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH 4FDA News & Notes - Week of November 14, 2011 2FDA News & Notes - Week of November 14, 2011 3FDA News & Notes - Week of November 14, 2011 4
(Date:9/30/2014)... September 30, 2014 A group of Americans ... combat an epidemic that, left unchecked, could create a catastrophic, ... not headed to Africa. John Rogers, the Executive Director the ... Korea to fight a disease most think mankind conquered long ... 80 years ago is on the comeback in several countries ...
(Date:9/30/2014)... Beach, Florida (PRWEB) September 30, 2014 Two ... make the treatment of gum disease a far ... of the past. , “If you’ve ever felt electric shock ... cream or sip a cold beverage, it’s possible you already ... Salisbury , who is a general dentist in West Palm ...
(Date:9/30/2014)... 2014 (HealthDay News) -- Medicare should cover low-dose computed ... for the disease, a coalition of more than 60 ... includes the Lung Cancer Alliance, the Society of Thoracic ... Society and the American Society of Clinical Oncology, made ... U.S. Centers for Medicare & Medicaid Services (CMS). ...
(Date:9/30/2014)... of Defense has made progress in reducing the stigma ... depression and post-traumatic stress disorder, but more improvement is ... , Despite efforts of both the Defense Department and ... many service members still do not seek needed care ... a concerted effort to promote treatment as a way ...
(Date:9/30/2014)... ANN ARBORThe discovery of a gene mutation that causes ... development of drugs that block the rapid, unstoppable cell ... at the University of Michigan and the U-M Health ... devastating disease dyskeratosis congenita, in which precious hematopoietic stem ... DC age prematurely and are prone to cancer and ...
Breaking Medicine News(10 mins):Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 3Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 3Health News:Disease decoded: Gene mutation may lead to development of new cancer drugs 2
... Virginia Tech,s College of Natural Resources and Environment, has ... Mycobacterium tuberculosis complex, a group of pathogens that ... been nearly two decades since a new organism was ... the early and mid 20th century. Tuberculosis is ...
... HealthDay Reporter , WEDNESDAY, Sept. 29 (HealthDay News) ... women finds that screening can lower the risk of dying ... study, done in Sweden, found that women who were screened ... women five times over a 10-year period would save one ...
... from The Commonwealth Fund provides recommendations for state and ... health insurance exchanges which are a key element of ... state-based exchanges, to be set up by states and ... with subsidized health insurance for small businesses and individuals ...
... that also have mutations in the BRCA gene appear to ... the same disease without the deleterious genetic mutation, according to ... The findings may offer a direction for study of ... cancer patients, as well as highlight the unique need for ...
... By Amanda Gardner HealthDay Reporter , ... that releases a progestin hormone may be an effective ... researchers report. By delaying a total hysterectomy, which ... allows women to remain fertile and possibly to have ...
... WEDNESDAY, Sept. 29 (HealthDay News) -- Driven by reports of ... positioners are dangerous and should not be used. The ... Drug Administration (FDA) and the U.S. Consumer Product Safety Commission ... babies under 4 months old suffocated in the last ...
Cached Medicine News:Health News:Virginia Tech professor discovers new TB pathogen 2Health News:Virginia Tech professor discovers new TB pathogen 3Health News:Mammograms Save Lives for Women in Their 40s, Study Says 2Health News:Mammograms Save Lives for Women in Their 40s, Study Says 3Health News:New health insurance exchanges should be independent, aim for level playing field 2Health News:New health insurance exchanges should be independent, aim for level playing field 3Health News:Study finds women with triple negative breast cancer and BRCA mutations have lower risk of recurrence 2Health News:Study finds women with triple negative breast cancer and BRCA mutations have lower risk of recurrence 3Health News: IUD Proposed to Treat Uterine Cancer 2Health News: IUD Proposed to Treat Uterine Cancer 3Health News:Infant Sleep Positioners Dangerous, U.S. Health Officials Warn 2Health News:Infant Sleep Positioners Dangerous, U.S. Health Officials Warn 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: